Global Newsroom | CSL
Oct 24, 2024 · Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships. Oct 24, 2024 - MELBOURNE – 24 October 2024 – Two scientists have each been awarded CSL Centenary Fellowships, valued at …
News Releases - CSL
Oct 17, 2024 · CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...
News Releases - CSL
Oct 24, 2024 · Swissmedic Authorises CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B. CSL's HEMGENIX® is a one-time, single-dose treatment for male adults with severe/moderately severe hemophilia B BERN, Switzerland, Jan. 15, 2024 /PRNewswire/ -- Global biotechnology leader CSL... Dec 21, 2023.
News Releases | CSL
Nov 2, 2022 · MELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 / PRNewswire / -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health.
CSL Seqirus Begins Shipping Portfolio of Innovative Influenza …
Jul 17, 2023 · CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a...
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial ...
KING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).
News Releases - CSL
KING OF PRUSSIA, Pa., Feb. 26, 2023 / PRNewswire / -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL's investigational first-in-class monoclonal antibody being developed as a long-term prophylactic ...
News Releases - CSL
May 20, 2024 · CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both lab and office spaces.
CSL Opens New, State-of-the-Art Vaccine Research and …
Mar 27, 2023 · The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines . WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts.
CSL announces carbon emissions reduction targets
MELBOURNE, Australia, Aug. 16, 2022 / PRNewswire / -- CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader sustainability strategy to build a more sustainable future for employees, communities, patients and donors ...